BenÃ-cio N Frey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1565641/publications.pdf

Version: 2024-02-01

271 papers

11,588 citations

51 h-index 97 g-index

280 all docs

280 docs citations

times ranked

280

11537 citing authors

#	Article	IF	CITATIONS
1	Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 2018, 20, 97-170.	1.9	1,079
2	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders, 2013, 15, 1-44.	1.9	740
3	Oxidative stress markers in bipolar disorder: A meta-analysis. Journal of Affective Disorders, 2008, 111, 135-144.	4.1	442
4	Allostatic load in bipolar disorder: Implications for pathophysiology and treatment. Neuroscience and Biobehavioral Reviews, 2008, 32, 675-692.	6.1	416
5	Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neuroscience Letters, 2006, 398, 215-219.	2.1	343
6	Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a doubleâ€blind, randomized, placeboâ€controlled study. Human Psychopharmacology, 2008, 23, 87-94.	1.5	255
7	Clinical implications of a staging model for bipolar disorders. Expert Review of Neurotherapeutics, 2009, 9, 957-966.	2.8	214
8	Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sciences, 2006, 79, 281-286.	4.3	211
9	Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Australian and New Zealand Journal of Psychiatry, 2013, 47, 321-332.	2.3	193
10	From anatomy to function: the role of the somatosensory cortex in emotional regulation. Revista Brasileira De Psiquiatria, 2019, 41, 261-269.	1.7	184
11	Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. Journal of Psychiatry and Neuroscience, 2006, 31, 326-32.	2.4	176
12	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. Canadian Journal of Psychiatry, 2016, 61, 588-603.	1.9	165
13	The role of hippocampus in the pathophysiology of bipolar disorder. Behavioural Pharmacology, 2007, 18, 419-430.	1.7	149
14	Three-Dimensional Mapping of Hippocampal Anatomy in Unmedicated and Lithium-Treated Patients with Bipolar Disorder. Neuropsychopharmacology, 2008, 33, 1229-1238.	5.4	148
15	Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder. Oxidative Medicine and Cellular Longevity, 2012, 2012, 1-13.	4.0	147
16	Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Review of Neurotherapeutics, 2008, 8, 1101-1113.	2.8	146
17	DNA damage in bipolar disorder. Psychiatry Research, 2007, 153, 27-32.	3.3	145
18	MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. Nature Communications, 2017, 8, 15497.	12.8	144

#	Article	IF	Citations
19	Disruption in the Blood-Brain Barrier: The Missing Link between Brain and Body Inflammation in Bipolar Disorder?. Neural Plasticity, 2015, 2015, 1-12.	2.2	139
20	Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes. Revista Brasileira De Psiquiatria, 2008, 30, 243-245.	1.7	129
21	Comparative Efficacy of the Generalized Anxiety Disorder 7-Item Scale and the Edinburgh Postnatal Depression Scale as Screening Tools for Generalized Anxiety Disorder in Pregnancy and the Postpartum Period. Canadian Journal of Psychiatry, 2014, 59, 434-440.	1.9	126
22	The Clinical Implications Of Cognitive Impairment and Allostatic Load in Bipolar Disorder. European Psychiatry, 2013, 28, 21-29.	0.2	119
23	Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry, 2016, 16, 105.	2.6	114
24	Depression in Women. Journal of Clinical Psychiatry, 2011, 72, e1563-e1569.	2.2	114
25	Cortical thickness in major depressive disorder: A systematic review and meta-analysis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 88, 287-302.	4.8	113
26	Investigation of serum high-sensitive C-reactive protein levels across all mood states in bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 300-304.	3.2	109
27	Neuronal Correlates of Brain-derived Neurotrophic Factor Val66Met Polymorphism and Morphometric Abnormalities in Bipolar Disorder. Neuropsychopharmacology, 2009, 34, 1904-1913.	5.4	109
28	Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medication-free individuals with bipolar disorder: an in vivo1H MRS study. Bipolar Disorders, 2007, 9, 119-127.	1.9	107
29	Resting-state functional connectivity in individuals with bipolar disorder during clinical remission: a systematic review. Journal of Psychiatry and Neuroscience, 2018, 43, 298-316.	2.4	106
30	Increased oxidative stress and DNA damage in bipolar disorder: A twin-case report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 283-285.	4.8	104
31	Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disorders, 2006, 8, 275-280.	1.9	95
32	Changes in Antioxidant Defense Enzymes after d-amphetamine Exposure: Implications as an Animal Model of Mania. Neurochemical Research, 2006, 31, 699-703.	3.3	90
33	Increased serum glial cell line-derived neurotrophic factor immunocontent during manic and depressive episodes in individuals with bipolar disorder. Neuroscience Letters, 2006, 407, 146-150.	2.1	84
34	Insight, quality of life and cognitive functioning in euthymic patients with bipolar disorder. Journal of Affective Disorders, 2008, 110, 75-83.	4.1	82
35	Cognitive function and serum levels of brainâ€derived neurotrophic factor in patients with bipolar disorder. Bipolar Disorders, 2009, 11, 663-671.	1.9	80
36	Depression during menopausal transition: a review of treatment strategies and pathophysiological correlates. Menopause International, 2008, 14, 123-128.	1.6	79

#	Article	IF	CITATIONS
37	The use of cannabinoids for sleep: A critical review on clinical trials Experimental and Clinical Psychopharmacology, 2019, 27, 383-401.	1.8	79
38	Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Research, 2006, 1097, 224-229.	2.2	75
39	Early intervention in bipolar disorders: Clinical, biochemical and neuroimaging imperatives. Journal of Affective Disorders, 2009, 114, 1-13.	4.1	7 5
40	Anxiety Comorbidity and Quality of Life in Bipolar Disorder Patients. Canadian Journal of Psychiatry, 2007, 52, 175-181.	1.9	67
41	The association between biological rhythms, depression, and functioning in bipolar disorder: a large multiâ€center study. Acta Psychiatrica Scandinavica, 2016, 133, 102-108.	4.5	66
42	DNA damage in rats after treatment with methylphenidate. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 1282-1288.	4.8	64
43	Risk factors of new onset anxiety and anxiety exacerbation in the perinatal period: A systematic review and meta-analysis. Journal of Affective Disorders, 2018, 238, 626-635.	4.1	63
44	Illness duration and total brain gray matter in bipolar disorder: Evidence for neurodegeneration?. European Neuropsychopharmacology, 2008, 18, 717-722.	0.7	62
45	Preeclampsia as a risk factor for postpartum depression and psychosis: a systematic review and meta-analysis. Archives of Women's Mental Health, 2020, 23, 493-505.	2.6	62
46	Effects of mood stabilizers on DNA damage in an animal model of mania. Journal of Psychiatry and Neuroscience, 2008, 33, 516-24.	2.4	62
47	Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder. Journal of Clinical Psychiatry, 2019, 80, .	2.2	61
48	Cognitive-behavioral group treatment for perinatal anxiety: a pilot study. Archives of Women's Mental Health, 2015, 18, 631-638.	2.6	60
49	Changes in cortical thickness across the lifespan in major depressive disorder. Psychiatry Research - Neuroimaging, 2013, 214, 204-211.	1.8	59
50	The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study. Journal of Affective Disorders, 2018, 227, 542-549.	4.1	59
51	Serum neurotrophin-3 is increased during manic and depressive episodes in bipolar disorder. Neuroscience Letters, 2007, 415, 87-89.	2.1	58
52	Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review. Alcoholism: Clinical and Experimental Research, 2019, 43, 550-563.	2.4	56
53	The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Conce L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.	r n ant	54
54	Canadian Journal of Psychiatry, 2021, 66, 113-125. Non-Hormonal Treatment Strategies for Vasomotor Symptoms. Drugs, 2011, 71, 287-304.	10.9	52

#	Article	IF	CITATIONS
55	Assessing intracortical myelin in the living human brain using myelinated cortical thickness. Frontiers in Neuroscience, 2015, 9, 396.	2.8	52
56	Val66met polymorphism and serum brain-derived neurotrophic factor levels in bipolar disorder. Molecular Psychiatry, 2007, 12, 230-231.	7.9	51
57	Effects of lithium and valproate on serum and hippocampal neurotrophin-3 levels in an animal model of mania. Journal of Psychiatric Research, 2008, 42, 416-421.	3.1	51
58	Sex hormones and biomarkers of neuroprotection and neurodegeneration: implications for female reproductive events in bipolar disorder. Bipolar Disorders, 2014, 16, 48-57.	1.9	50
59	Mismatch between self-reported quality of life and functional assessment in acute mania: A matter of unawareness of illness?. Journal of Affective Disorders, 2007, 103, 247-252.	4.1	49
60	Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression. JAMA Network Open, 2020, 3, e1918377.	5.9	49
61	Measuring circadian function in bipolar disorders: Empirical and conceptual review of physiological, actigraphic, and selfâ€report approaches. Bipolar Disorders, 2020, 22, 693-710.	1.9	49
62	Relationship between inflammatory biomarkers and depressive symptoms during late pregnancy and the early postpartum period: a longitudinal study. Revista Brasileira De Psiquiatria, 2016, 38, 190-196.	1.7	48
63	Structural and functional changes in the somatosensory cortex in euthymic females with bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1075-1083.	2.3	48
64	Association of functioning and quality of life with objective and subjective measures of sleep and biological rhythms in major depressive and bipolar disorder. Australian and New Zealand Journal of Psychiatry, 2019, 53, 683-696.	2.3	48
65	Influence of endogenous estradiol, progesterone, allopregnanolone, and dehydroepiandrosterone sulfate on brain resting state functional connectivity across the menstrual cycle. Fertility and Sterility, 2017, 107, 1246-1255.e4.	1.0	47
66	Sensitivity and Specificity of the Mood Disorder Questionnaire as a Screening Tool for Bipolar Disorder During Pregnancy and the Postpartum Period. Journal of Clinical Psychiatry, 2012, 73, 1456-1461.	2.2	46
67	Sensitization and cross-sensitization after chronic treatment with methylphenidate in adolescent Wistar rats. Behavioural Pharmacology, 2007, 18, 205-212.	1.7	45
68	The rapid effects of estrogen: a mini-review. Behavioural Pharmacology, 2010, 21, 465-472.	1.7	45
69	Resting state functional connectivity in women with bipolar disorder during clinical remission. Bipolar Disorders, 2017, 19, 97-106.	1.9	43
70	Functional and cognitive impairment in the first episode of depression: A systematic review. Acta Psychiatrica Scandinavica, 2022, 145, 156-185.	4.5	42
71	Lithium increases nerve growth factor levels in the rat hippocampus in an animal model of mania. Behavioural Pharmacology, 2006, 17, 311-318.	1.7	41
72	Gender differences in α-[11C]MTrp brain trapping, an index of serotonin synthesis, in medication-free individuals with major depressive disorder: A positron emission tomography study. Psychiatry Research - Neuroimaging, 2010, 183, 157-166.	1.8	40

#	Article	IF	CITATIONS
73	Update on bipolar disorder biomarker candidates. Expert Review of Molecular Diagnostics, 2016, 16, 1209-1220.	3.1	38
74	Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis. Psychological Medicine, 2021, 51, 2742-2751.	4.5	38
75	Altered intracortical myelin staining in the dorsolateral prefrontal cortex in severe mental illness. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 369-376.	3.2	37
76	Cognitive behavior therapy for menopausal symptoms (CBT-Meno). Menopause, 2019, 26, 972-980.	2.0	37
77	Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report. Neuropsychopharmacology, 2020, 45, 283-291.	5.4	37
78	The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols. Journal of Psychiatry and Neuroscience, 2019, 44, 223-236.	2.4	37
79	Neurobiological and behavioral mechanisms of circadian rhythm disruption in bipolar disorder: A critical multiâ€disciplinary literature review and agenda for future research from the ISBD task force on chronobiology. Bipolar Disorders, 2022, 24, 232-263.	1.9	36
80	Manic symptoms and quality of life in bipolar disorder. Psychiatry Research, 2007, 153, 33-38.	3.3	35
81	Ageâ€related mapping of intracortical myelin from late adolescence to middle adulthood using T ₁ â€weighted MRI. Human Brain Mapping, 2017, 38, 3691-3703.	3.6	35
82	Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Archives of Women's Mental Health, 2017, 20, 713-719.	2.6	35
83	Non-pharmacological interventions for improving postpartum maternal sleep: A systematic review and meta-analysis. Sleep Medicine Reviews, 2018, 41, 87-100.	8.5	35
84	Challenges and Opportunities to Manage Depression During the Menopausal Transition and Beyond. Psychiatric Clinics of North America, 2010, 33, 295-308.	1.3	33
85	Increased illness burden in women with comorbid bipolar and premenstrual dysphoric disorder: data from 1 099 women from STEPâ€BD study. Acta Psychiatrica Scandinavica, 2017, 136, 473-482.	4.5	33
86	Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. Translational Psychiatry, 2019, 9, 254.	4.8	33
87	A longitudinal study of neurotrophic, oxidative, and inflammatory markers in first-onset depression in midlife women. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 771-781.	3.2	32
88	Cognitive behavioral therapy for perinatal anxiety: A randomized controlled trial. Australian and New Zealand Journal of Psychiatry, 2020, 54, 423-432.	2.3	32
89	Multisite Comparison of MRI Defacing Software Across Multiple Cohorts. Frontiers in Psychiatry, 2021, 12, 617997.	2.6	32
90	Brain age in mood and psychotic disorders: a systematic review and metaâ€analysis. Acta Psychiatrica Scandinavica, 2022, 145, 42-55.	4.5	32

#	Article	IF	CITATIONS
91	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. Bipolar Disorders, 2021, 23, 767-788.	1.9	32
92	Investigating the relationship between objective measures of sleep and self-report sleep quality in healthy adults: a review. Journal of Clinical Sleep Medicine, 2022, 18, 927-936.	2.6	32
93	Do changes in subjective sleep and biological rhythms predict worsening in postpartum depressive symptoms? A prospective study across the perinatal period. Archives of Women's Mental Health, 2016, 19, 591-598.	2.6	31
94	Performance of the biological rhythms interview for assessment in neuropsychiatry: An item response theory and actigraphy analysis. Journal of Affective Disorders, 2018, 225, 54-63.	4.1	31
95	Validation of the Brazilian Portuguese version of the Premenstrual Symptoms Screening Tool (PSST) and association of PSST scores with health-related quality of life. Revista Brasileira De Psiquiatria, 2017, 39, 140-146.	1.7	30
96	Alterations in circadian rhythms are associated with increased lipid peroxidation in females with bipolar disorder. International Journal of Neuropsychopharmacology, 2014, 17, 715-722.	2.1	29
97	Depressive-like behaviours and decreased dendritic branching in the medial prefrontal cortex of mice with tumors: A novel validated model of cancer-induced depression. Behavioural Brain Research, 2015, 294, 25-35.	2.2	29
98	Biological and psychosocial predictors of anxiety worsening in the postpartum period: A longitudinal study. Journal of Affective Disorders, 2019, 250, 218-225.	4.1	29
99	Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression. Scientific Reports, 2017, 7, 7473.	3.3	28
100	Correlation between serotonin synthesis and 5-HT1A receptor binding in the living human brain: A combined α-[11C]MT and [18F]MPPF positron emission tomography study. NeuroImage, 2008, 42, 850-857.	4.2	27
101	Differential biomarker signatures in unipolar and bipolar depression: A machine learning approach. Australian and New Zealand Journal of Psychiatry, 2020, 54, 393-401.	2.3	27
102	The Early Burden of Disability in Individuals With Mood and Other Common Mental Disorders in Ontario, Canada. JAMA Network Open, 2020, 3, e2020213.	5.9	27
103	Consensus on nomenclature for clinical staging models in bipolar disorder: A narrative review from the International Society for Bipolar Disorders (ISBD) Staging Task Force. Bipolar Disorders, 2021, 23, 659-678.	1.9	27
104	Increased cerebral oxidative damage and decreased antioxidant defenses in ovariectomized and sham-operated rats supplemented with vitamin A. Cell Biology and Toxicology, 2012, 28, 317-330.	5.3	26
105	The impact of obesity on neuropsychological functioning in adults with and without major depressive disorder. PLoS ONE, 2017, 12, e0176898.	2.5	26
106	The Role of Circadian Rhythms in Postpartum Sleep and Mood. Sleep Medicine Clinics, 2018, 13, 359-374.	2.6	26
107	A proton magnetic resonance spectroscopy investigation of the dorsolateral prefrontal cortex in acute mania. Human Psychopharmacology, 2005, 20, 133-139.	1.5	24
108	Brain-derived neurotrophic factor val66met polymorphism affects prefrontal energy metabolism in bipolar disorder. NeuroReport, 2007, 18, 1567-1570.	1.2	24

#	Article	IF	CITATIONS
109	Testing a deep convolutional neural network for automated hippocampus segmentation in a longitudinal sample of healthy participants. Neurolmage, 2019, 197, 589-597.	4.2	24
110	Suicidal Risk in Women with Premenstrual Syndrome and Premenstrual Dysphoric Disorder: A Systematic Review and Meta-Analysis. Journal of Women's Health, 2021, 30, 1693-1707.	3.3	24
111	A Pilot, 8-Week, Placebo Lead-In Trial of Quetiapine Extended Release for Depression in Midlife Women. Journal of Clinical Psychopharmacology, 2010, 30, 612-615.	1.4	23
112	Val66Met polymorphism and serum brainâ€derived neurotrophic factor in bipolar disorder: an openâ€label trial. Acta Psychiatrica Scandinavica, 2014, 129, 393-400.	4.5	23
113	Brain Structure and Function in Women with Comorbid Bipolar and Premenstrual Dysphoric Disorder. Frontiers in Psychiatry, 2017, 8, 301.	2.6	23
114	Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. Neuropsychopharmacology, 2020, 45, 1390-1397.	5.4	23
115	Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. Psychological Medicine, 2019, 49, 1629-1638.	4.5	22
116	Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. Translational Psychiatry, 2021, 11, 127.	4.8	22
117	Sleep, daily activity rhythms and postpartum mood: A longitudinal study across the perinatal period. Chronobiology International, 2016, 33, 791-801.	2.0	21
118	White Matter Indices of Medication Response in Major Depression: A Diffusion Tensor Imaging Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2019, 4, 913-924.	1.5	21
119	Effect of obesity on cognition in adults with and without a mood disorder: study design and methods. BMJ Open, 2016, 6, e009347.	1.9	20
120	Effects of a 12-week running programme in youth and adults with complex mood disorders. BMJ Open Sport and Exercise Medicine, 2018, 4, e000314.	2.9	20
121	Reduced accuracy accompanied by reduced neural activity during the performance of an emotional conflict task by unmedicated patients with major depression: A CAN-BIND fMRI study. Journal of Affective Disorders, 2019, 257, 765-773.	4.1	20
122	Comorbid bipolar disorder and premenstrual dysphoric disorder: real patients, unanswered questions. Archives of Women's Mental Health, 2013, 16, 79-81.	2.6	19
123	Biological rhythms are independently associated with quality of life in bipolar disorder. International Journal of Bipolar Disorders, 2016, 4, 9.	2.2	19
124	Subtle persistent working memory and selective attention deficits in women with premenstrual syndrome. Psychiatry Research, 2017, 249, 354-362.	3.3	19
125	Behavioural Effects of Using Sulfasalazine to Inhibit Glutamate Released by Cancer Cells: A Novel target for Cancer-Induced Depression. Scientific Reports, 2017, 7, 41382.	3.3	19
126	Rhythmicity of Mood Symptoms in Individuals at Risk for Psychiatric Disorders. Scientific Reports, 2018, 8, 11402.	3.3	19

#	Article	IF	CITATIONS
127	Shift in the brain network of emotional regulation in midlife women. Menopause, 2010, 17, 840-845.	2.0	18
128	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1173-1182.	2.3	18
129	Toward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data. Journal of Affective Disorders, 2020, 272, 508-520.	4.1	18
130	Approach to Premenstrual Dysphoria for the Mental Health Practitioner. Psychiatric Clinics of North America, 2010, 33, 257-272.	1.3	17
131	Biological rhythms, metabolic syndrome and current depressive episode in a community sample. Psychoneuroendocrinology, 2016, 72, 34-39.	2.7	17
132	Childhood maltreatment and cognitive functioning in patients with major depressive disorder: a CAN-BIND-1 report. Psychological Medicine, 2020, 50, 2536-2547.	4.5	17
133	Prolonged Subdural Infusion of Kynurenic Acid Is Associated with Dose-Dependent Myelin Damage in the Rat Spinal Cord. PLoS ONE, 2015, 10, e0142598.	2.5	17
134	Clinical utility of combinatorial pharmacogenomic testing in depression: A Canadian patient- and rater-blinded, randomized, controlled trial. Translational Psychiatry, 2022, 12, 101.	4.8	17
135	Effort-based decision-making is affected by overweight/obesity in major depressive disorder. Journal of Affective Disorders, 2019, 256, 221-227.	4.1	16
136	Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report. Communications Biology, 2021, 4, 903.	4.4	16
137	Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment. Journal of Clinical Psychiatry, 2019, 80, .	2.2	16
138	Evidence of astrogliosis in rat hippocampus after d-amphetamine exposure. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 1231-1234.	4.8	15
139	Treating comorbid premenstrual dysphoric disorder in women with bipolar disorder. Journal of Psychiatry and Neuroscience, 2016, 41, E22-E23.	2.4	15
140	Comorbid Premenstrual Dysphoric Disorder and Bipolar Disorder: A Review. Frontiers in Psychiatry, 2021, 12, 719241.	2.6	15
141	Melatonin use during pregnancy and lactation: A scoping review of human studies. Revista Brasileira De Psiquiatria, 2022, 44, 342-348.	1.7	15
142	The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. Bipolar Disorders, 2013, 15, 58-60.	1.9	14
143	Age-related deficits in intracortical myelination in young adults with bipolar disorder type I. Journal of Psychiatry and Neuroscience, 2019, 44, 79-88.	2.4	14
144	The relationship between parental bonding and mood, anxiety and related disorders in adulthood: A systematic review and meta-analysis. Journal of Affective Disorders, 2022, 307, 221-236.	4.1	14

#	Article	IF	CITATIONS
145	Effects of quetiapine extended release on sleep and quality of life in midlife women with major depressive disorder. Archives of Women's Mental Health, 2013, 16, 83-85.	2.6	13
146	Association of intracortical myelin and cognitive function in bipolar I disorder. Acta Psychiatrica Scandinavica, 2018, 138, 62-72.	4.5	13
147	Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report. NeuroImage: Clinical, 2021, 32, 102864.	2.7	13
148	Mild Depressive Symptoms During the Third Trimester of Pregnancy Are Associated with Disruptions in Daily Rhythms but Not Subjective Sleep Quality. Journal of Women's Health, 2016, 25, 594-598.	3.3	12
149	Convergent lines of evidence support the role of uric acid levels as a potential biomarker in bipolar disorder. Expert Review of Molecular Diagnostics, 2017, 17, 107-108.	3.1	12
150	Explicit emotional memory biases in mood disorders: A systematic review. Psychiatry Research, 2019, 278, 162-172.	3.3	12
151	Adjunctive tianeptine treatment for bipolar disorder: A 24-week randomized, placebo-controlled, maintenance trial. Journal of Psychopharmacology, 2019, 33, 502-510.	4.0	12
152	Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report. International Journal of Neuropsychopharmacology, 2020, 23, 88-95.	2.1	12
153	Electrophysiological correlates of sleep disturbance induced by acute and chronic administration of d-amphetamine. Brain Research, 2009, 1249, 162-172.	2.2	11
154	Brainâ€derived neurotrophic factor in bipolar disorder: beyond <i>trait</i> and <i>state</i> : comment on †Decreased levels of serum brainâ€derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar I and II disorders'. Bipolar Disorders, 2009, 11, 221-222.	1.9	11
155	The Mood Rhythm Instrument: development and preliminary report. Revista Brasileira De Psiquiatria, 2016, 38, 148-153.	1.7	11
156	Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110194.	4.8	11
157	5-year incidence of suicide-risk in youth: A gradient tree boosting and SHAP study. Journal of Affective Disorders, 2021, 295, 1049-1056.	4.1	11
158	The Depression Inventory Development Workgroup: A Collaborative, Empirically Driven Initiative to Develop a New Assessment Tool for Major Depressive Disorder. Innovations in Clinical Neuroscience, 2016, 13, 20-31.	0.1	11
159	Emotional memory in pregnant women at risk for postpartum depression. Psychiatry Research, 2015, 229, 777-783.	3.3	10
160	<scp>RNA</scp> â€sequencing profiles hippocampal gene expression in a validated model of cancerâ€induced depression. Genes, Brain and Behavior, 2016, 15, 711-721.	2.2	10
161	Quality assurance assessment of a specialized perinatal mental health clinic. BMC Pregnancy and Childbirth, 2020, 20, 485.	2.4	10
162	An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report. NeuroImage: Clinical, 2020, 25, 102178.	2.7	10

#	Article	IF	CITATIONS
163	Novel mechanism of action for the mood stabilizer lithium. Bipolar Disorders, 2021, 23, 76-83.	1.9	10
164	Predicting Brain Age at Slice Level: Convolutional Neural Networks and Consequences for Interpretability. Frontiers in Psychiatry, 2021, 12, 598518.	2.6	10
165	An investigation of cannabis use for insomnia in depression and anxiety in a naturalistic sample. BMC Psychiatry, 2022, 22, 303.	2.6	10
166	Decreased Expression of Cerebral Dopamine Neurotrophic Factor in Platelets of Stroke Patients. Journal of Stroke and Cerebrovascular Diseases, 2020, 29, 104502.	1.6	9
167	Structural and Functional Brain Correlates of Neuroprogression in Bipolar Disorder. Current Topics in Behavioral Neurosciences, 2020, 48, 197-213.	1.7	9
168	Lifetime cocaine use is a potential predictor for conversion from major depressive disorder to bipolar disorder: A prospective study. Psychiatry and Clinical Neurosciences, 2020, 74, 418-423.	1.8	9
169	Sleep and Circadian Rhythm Disturbances in Bipolar Disorder. Journal of Clinical Psychiatry, 2011, 72, 724.	2.2	9
170	Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder. Journal of Clinical Psychiatry, 2020, 81, .	2.2	9
171	The prevalence of borderline personality features and borderline personality disorder during the perinatal period: a systematic review and meta-analysis. Archives of Women's Mental Health, 2022, 25, 277-289.	2.6	9
172	Expert consensus recommendations on the use of randomized clinical trials for drug approval in psychiatry- comparing trial designs. European Neuropsychopharmacology, 2022, 60, 91-99.	0.7	9
173	A statistical method to calculate blood contamination in the measurement of salivary hormones in healthy women. Clinical Biochemistry, 2017, 50, 436-439.	1.9	8
174	Effects of Estradiol Therapy on Resting-State Functional Connectivity of Transgender Women After Gender-Affirming Related Gonadectomy. Frontiers in Neuroscience, 2019, 13, 817.	2.8	8
175	Exploring brain connectivity changes in major depressive disorder using <scp>functionalâ€structural</scp> data fusion: A CANâ€BINDâ€1 study. Human Brain Mapping, 2021, 42, 4940-4957.	3.6	8
176	Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report. Psychoneuroendocrinology, 2021, 132, 105348.	2.7	8
177	The Use of Cannabinoids for Insomnia in Daily Life: Naturalistic Study. Journal of Medical Internet Research, 2021, 23, e25730.	4.3	8
178	Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report. NeuroImage: Clinical, 2022, 35, 103120.	2.7	8
179	Prospective Assessment of Daily Patterns of Mood-Related Symptoms. Frontiers in Psychiatry, 2018, 9, 370.	2.6	7
180	Reliability of a functional magnetic resonance imaging task of emotional conflict in healthy participants. Human Brain Mapping, 2020, 41, 1400-1415.	3.6	7

#	Article	IF	CITATIONS
181	Cognitive Behavior Therapy for Women With Generalized Anxiety Disorder in the Perinatal Period: Impact on Problematic Behaviors. Behavior Therapy, 2021, 52, 907-916.	2.4	7
182	Association between discrepancy in objective and subjective cognitive abilities and treatment response in patients with major depressive disorder: A CAN-BIND-1 study report. Journal of Affective Disorders, 2021, 295, 1095-1101.	4.1	7
183	Validation of the intolerance of uncertainty scale as a screening tool for perinatal anxiety. BMC Pregnancy and Childbirth, 2021, 21, 829.	2.4	7
184	Glial fibrillary acidic protein expression after electroconvulsive shocks in rat brain. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2006, 30, 663-667.	4.8	6
185	Mitochondrial Dysfunction in Bipolar Disorder: Lessons from Brain Imaging and Molecular Markers. Revista Colombiana De PsiquiatrÃa, 2011, 40, 166S-182S.	0.3	6
186	Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study. Journal of Affective Disorders, 2020, 264, 414-424.	4.1	6
187	Validation of the English version of the Mood Rhythm Instrument. BMC Psychology, 2020, 8, 35.	2.1	6
188	Baseline Functional Connectivity in Resting State Networks Associated with Depression and Remission Status after 16ÂWeeks of Pharmacotherapy: A CAN-BIND Report. Cerebral Cortex, 2022, 32, 1223-1243.	2.9	6
189	Is there a role for estrogen in treating depression during menopause?. Journal of Psychiatry and Neuroscience, 2010, 35, E6-E7.	2.4	6
190	THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial. Innovations in Clinical Neuroscience, 2020, 17, 30-40.	0.1	6
191	"One Degree of Separation― A Mixed-Methods Evaluation of Canadian Mental Health Care User and Provider Experiences With Remote Care During COVID-19. Canadian Journal of Psychiatry, 2022, , 070674372110706.	1.9	6
192	Longitudinal Changes in Sleep, Biological Rhythms, and Light Exposure From Late Pregnancy to Postpartum and Their Impact on Peripartum Mood and Anxiety. Journal of Clinical Psychiatry, 2022, 83, .	2.2	6
193	Evaluation of an Augmented Cognitive Behavioural Group Therapy for Perinatal Generalized Anxiety Disorder (GAD) during the COVID-19 Pandemic. Journal of Clinical Medicine, 2022, 11, 209.	2.4	6
194	Corrected values of brain metabolites for the article: â€~Abnormal cellular energy and phospholipid metabolism in the left dorsolateral prefrontal cortex of medicationâ€free individuals with bipolar disorder: an <i>in vivo</i> ¹ H MRS study'. Bipolar Disorders, 2008, 10, 849-849.	1.9	5
195	Neural correlates of verbal recognition memory in obese adults with and without major depressive disorder. Brain and Behavior, 2020, 10, e01848.	2.2	5
196	Physician suicide demographics and the COVID-19 pandemic. Revista Brasileira De Psiquiatria, 2022, 44, 124-135.	1.7	5
197	Effective recommendations towards healthy routines to preserve mental health during the COVID-19 pandemic. Revista Brasileira De Psiquiatria, 2022, 44, 136-146.	1.7	5
198	Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. Canadian Journal of Psychiatry, 2023, 68, 299-311.	1.9	5

#	Article	IF	Citations
199	Salivary cortisol during memory encoding in pregnancy predicts postpartum depressive symptoms: a longitudinal study. Trends in Psychiatry and Psychotherapy, 2017, 39, 280-284.	0.8	4
200	Volumetric MRI Analysis of a Case of Severe Ventriculomegaly. Frontiers in Human Neuroscience, 2018, 12, 495.	2.0	4
201	The Menopause Visual Analogue Scale: a new tool for measuring the severity and response to treatment of symptoms throughout the menopausal transition. Climacteric, 2018, 21, 502-508.	2.4	4
202	Validation and psychometric properties of the Spanish Mood Rhythm Instrument. Biological Rhythm Research, 2022, 53, 841-853.	0.9	4
203	The Link between Estradiol and Neuroplasticity in Transgender Women after Gender-Affirming Surgery: A Bimodal Hypothesis. Neuroendocrinology, 2020, 110, 489-500.	2.5	4
204	Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkers. Journal of Affective Disorders, 2020, 263, 353-366.	4.1	4
205	Objective and subjective vasomotor symptom outcomes in the CBT-Meno randomized controlled trial. Climacteric, 2020, 23, 482-488.	2.4	4
206	Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. CNS Drugs, 2021, 35, 291-304.	5.9	4
207	Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report. CNS Drugs, 2021, 35, 439-450.	5.9	4
208	White matter microstructure in youth at risk for serious mental illness: A comparative analysis. Psychiatry Research - Neuroimaging, 2021, 312, 111289.	1.8	4
209	Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1. PLoS ONE, 2021, 16, e0253023.	2.5	4
210	Cognitive complaints in individuals recently diagnosed with bipolar disorder: A cross-sectional study. Psychiatry Research, 2021, 300, 113894.	3.3	4
211	Risk factors for new-onset bipolar disorder in a community cohort: A five-year follow up study. Psychiatry Research, 2021, 303, 114109.	3.3	4
212	The role of emotion dysregulation in cognitive behavioural group therapy for perinatal anxiety: Results from a randomized controlled trial and routine clinical care. Journal of Affective Disorders, 2021, 292, 517-525.	4.1	4
213	Depression During the Menopausal Transition: An Update on Epidemiology and Biological Treatments. Focus (American Psychiatric Publishing), 2012, 10, 22-27.	0.8	3
214	Altered hippocampal function with preserved cognitive performance in treatment-naive major depressive disorder. NeuroReport, 2019, 30, 46-52.	1.2	3
215	Cerebral cortical thickness after treatment with desvenlafaxine succinate in major depressive disorder. NeuroReport, 2019, 30, 378-382.	1.2	3
216	Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response. Translational Psychiatry, 2021, 11, 439.	4.8	3

#	Article	IF	CITATIONS
217	Bipolar Disorder in Women: Menstrual Cycle, Perinatal Period, and Menopause Transition., 2020,, 59-71.		3
218	Baseline anxiety, and early anxiety/depression improvement in anxious depression predicts treatment outcomes with escitalopram: A CAN-BIND-1 study report. Journal of Affective Disorders, 2022, 300, 50-58.	4.1	3
219	Characterizing worry content and impact in pregnant and postpartum women with anxiety disorders during COVIDâ€19. Clinical Psychology and Psychotherapy, 2021, , .	2.7	3
220	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. Frontiers in Psychiatry, 2022, 13, 816465.	2.6	3
221	Intolerance of Uncertainty and Perfectionistic Beliefs About Parenting as Cognitive Mechanisms of Symptom Change During Cognitive Behavior Therapy for Perinatal Anxiety. Behavior Therapy, 2022, 53, 738-750.	2.4	3
222	Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy. Brain and Behavior, 2022, 12, e2555.	2.2	3
223	A pilot study examining the effectiveness of a short-term, DBT informed, skills group for emotion dysregulation during the perinatal period Psychological Services, 2023, 20, 697-707.	1.5	3
224	Managing Depression and Anxiety during the Menopausal Transition and Beyond: The Window of Vulnerability. Key Issues in Mental Health, 2009, , 102-114.	0.6	2
225	A primary care-based treatment programme improves postpartum depression at 12â€months. Evidence-Based Mental Health, 2013, 16, 6-6.	4.5	2
226	Translational Research in Bipolar Disorders. Neural Plasticity, 2015, 2015, 1-3.	2.2	2
227	Impact of a structured, group-based running programme on clinical, cognitive and social function in youth and adults with complex mood disorders: a 12-week pilot study. BMJ Open Sport and Exercise Medicine, 2019, 5, e000521.	2.9	2
228	The Revised Mood Rhythm Instrument: A Large Multicultural Psychometric Study. Journal of Clinical Medicine, 2021, 10, 388.	2.4	2
229	Depression in midlife women attending a menopause clinic is associated with a history of childhood maltreatment. Climacteric, 2021 , , 1 - 5 .	2.4	2
230	Preliminary insights into the genetic architecture of postpartum depressive symptom severity using polygenic risk scores. Personalized Medicine in Psychiatry, 2021, 27-28, 100081.	0.1	2
231	Lifestyle predictors of depression and anxiety during COVID-19: a machine learning approach. Trends in Psychiatry and Psychotherapy, 2022, , .	0.8	2
232	New-onset psychosis following androgen deprivation therapy for prostate cancer. Canadian Journal of Urology, 2013, 20, 6868-70.	0.0	2
233	Investigating biological rhythms disruptions across the menstrual cycle in women with comorbid bipolar disorder and premenstrual dysphoric disorder. Archives of Women's Mental Health, 2022, 25, 345-353.	2.6	2
234	Magnetic Resonance Imaging Sequence Identification Using a Metadata Learning Approach. Frontiers in Neuroinformatics, $2021,15,622951.$	2.5	2

#	Article	IF	CITATIONS
235	Decreased Expression of Cerebral Dopamine Neurotrophic Factor in Platelets of Probable Alzheimer Patients. Alzheimer Disease and Associated Disorders, 2021, Publish Ahead of Print, .	1.3	2
236	Fluvoxamina no transtorno depressivo maior: um estudo multicêntrico aberto. Jornal Brasileiro De Psiquiatria, 2007, 56, 17-22.	0.7	1
237	Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated Bipolar Disorder Guidelines. Bipolar Disorders, 2013, 15, 338-339.	1.9	1
238	Pre-Treatment Resting-State Functional Connectivity Related to Anhedonia and Anxiety are Associated With Antidepressant Response to Escitalopram and Adjunct Aripiprazole. Biological Psychiatry, 2020, 87, S431.	1.3	1
239	Emotional reactivity and explicit emotional memory biases in major depressive disorder during euthymia. Psychiatry Research, 2020, 285, 112847.	3.3	1
240	Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report. Pharmacopsychiatry, 2021, 54, 225-231.	3.3	1
241	Interactions between neuroticism and stressful life events predict response to pharmacotherapy for major depression: A CANâ€BIND 1 report. Personality and Mental Health, 2021, 15, 273-282.	1.2	1
242	Identifying Nonlinear Patterns of 5-Year Suicide Risk Incidence in Youth: A Gradient Tree Boosting and SHAP Study. Biological Psychiatry, 2021, 89, S283.	1.3	1
243	Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report. Translational Psychiatry, 2021, 11 , 469 .	4.8	1
244	The role of depression in coronary artery disease. Arquivos Brasileiros De Cardiologia, 1999, 73, 237-250.	0.8	1
245	Quality of Life in Bipolar Disorder. , 2010, , 3591-3606.		1
246	Understanding the complex interplay between violence, depression and suicidal ideation in women: Time for a comprehensive sex- and gender-based approach. Revista Brasileira De Psiquiatria, 2020, 42, 467-468.	1.7	1
247	Adaptation and validation of the Mood Rhythm Instrument for use in Brazilian adolescents. Revista Brasileira De Psiquiatria, 2022, 44, 264-270.	1.7	1
248	Network properties of intracortical myelin associated with psychosocial functioning in bipolar I disorder. Bipolar Disorders, 2022, , .	1.9	1
249	Biophysical compartment models for single-shell diffusion MRI in the human brain: a model fitting comparison. Physics in Medicine and Biology, 2022, 67, 055009.	3.0	1
250	Conversion to major neurocognitive disorder after COVIDâ€19 in a woman with bipolar disorder: A 6â€year longitudinal case report. Bipolar Disorders, 2022, 24, 451-456.	1.9	1
251	A DSM-5-based tool to monitor concurrent mood and premenstrual symptoms: the McMaster Premenstrual and Mood Symptom Scale (MAC-PMSS). BMC Women's Health, 2022, 22, 96.	2.0	1
252	Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report. Psychiatry Research, 2022, 312, 114557.	3.3	1

#	Article	IF	Citations
253	P382. Replication of Personalized Relapse Prediction in Patients With Major Depressive Disorder Using Digital Biomarkers. Biological Psychiatry, 2022, 91, S241-S242.	1.3	1
254	Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report. Journal of Psychopharmacology, 2022, 36, 604-613.	4.0	1
255	Investigation of blood-brain barrier disruption in an animal model of mania induced by D-amphetamine. Journal of Affective Disorders Reports, 2022, 9, 100368.	1.7	1
256	Marcadores de estrés oxidativo en el trastorno bipolar: un metaanálisis. Psiquiatria Biologica, 2009, 16, 60-69.	0.1	0
257	Plasma Brain-Derived-Neurotrophic Factor levels and cognitive function in euthymic bipolar type I patients. Annals of General Psychiatry, 2010, 9, .	2.7	0
258	Soft Bipolar Spectrum and Staging in Bipolar Disorder. Current Psychiatry Reviews, 2013, 9, 33-40.	0.9	0
259	Oncodynamic Effect of Cancer on Depression. , 2016, , 105-127.		0
260	T97. Predicting Functioning and Quality of Life Using Objective and Subjective Measures of Sleep and Biological Rhythms in Major Depressive and Bipolar Disorder. Biological Psychiatry, 2019, 85, S166.	1.3	0
261	F107. Cortical Thickness Features Differentiate 16-Week Antidepressant Response Profiles in Major Depressive Disorder. Biological Psychiatry, 2019, 85, S254.	1.3	0
262	S124. Impact of CYP2C19 and CYP2D6 Genotypes on Clinical Outcomes and Side Effects in Patients Receiving Escitalopram and Aripiprazole for Major Depression: Results From the Can-Bind Cohort. Biological Psychiatry, 2019, 85, S344-S345.	1.3	0
263	Intracortical myelination. , 2021, , 417-426.		0
264	Daily Variability in Affective, Somatic, and Cognitive Symptoms Against Validated Scores of Anxiety and Depression: A Prospective Preliminary Study. Biological Psychiatry, 2021, 89, S111.	1.3	0
265	Sleep, biological rhythms and anxiety in the perinatal period: a systematic review protocol. BMJ Open, 2021, 11, e046767.	1.9	0
266	Cognition and Its Association with Psychosocial and Occupational Functioning during Treatment with Escitalopram in Patients with Major Depressive Disorder: A CAN-BIND-1 Report: La Cognition Et Son Association Avec Le Fonctionnement Psychosocial Et Professionnel Durant Le Traitement Par Escitalopram Chez Des Patients Souffrant De Trouble Dépressif Majeur: Une Étude Can-Bind-1. Canadian	1.9	0
267	Journal of Psychiatry, 2021, 66, 798-806. Cerebello-cerebral Functional Connectivity Networks in Major Depressive Disorder: a CAN-BIND-1 Study Report. Cerebellum, 2023, 22, 26-36.	2.5	0
268	Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2023, 8, 162-170.	1.5	0
269	Lifestyle Behaviors, Depression, and Anxiety Among Individuals Living in Canada During the COVID-19 Pandemic. American Journal of Lifestyle Medicine, 0, , 155982762211020.	1.9	0
270	Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 report. Journal of Affective Disorders Reports, 2022, 9, 100370.	1.7	0

#	Article	IF	CITATIONS
271	Acute and chronic stress predict anti-depressant treatment outcome and naturalistic course of major depression: A CAN-BIND report. Journal of Affective Disorders, 2022, 313, 8-14.	4.1	0